IL137706A0 - Mhc fusion proteins and conjugates - Google Patents
Mhc fusion proteins and conjugatesInfo
- Publication number
- IL137706A0 IL137706A0 IL13770699A IL13770699A IL137706A0 IL 137706 A0 IL137706 A0 IL 137706A0 IL 13770699 A IL13770699 A IL 13770699A IL 13770699 A IL13770699 A IL 13770699A IL 137706 A0 IL137706 A0 IL 137706A0
- Authority
- IL
- Israel
- Prior art keywords
- conjugates
- fusion proteins
- mhc fusion
- mhc
- proteins
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7535198P | 1998-02-19 | 1998-02-19 | |
PCT/US1999/003603 WO1999042597A1 (en) | 1998-02-19 | 1999-02-19 | Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
IL137706A0 true IL137706A0 (en) | 2001-10-31 |
Family
ID=22125136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13770699A IL137706A0 (en) | 1998-02-19 | 1999-02-19 | Mhc fusion proteins and conjugates |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1054984A1 (xx) |
JP (1) | JP2002504342A (xx) |
AU (1) | AU765378B2 (xx) |
BR (1) | BR9908082A (xx) |
CA (1) | CA2321262A1 (xx) |
IL (1) | IL137706A0 (xx) |
NZ (1) | NZ506071A (xx) |
WO (1) | WO1999042597A1 (xx) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458354B1 (en) | 1996-03-28 | 2002-10-01 | The Johns Hopkins University | Molecular complexes which modify immune responses |
US6015884A (en) | 1996-03-28 | 2000-01-18 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
DE19963859A1 (de) * | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
ES2747357T3 (es) * | 2001-03-14 | 2020-03-10 | Dako Denmark As | Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia |
GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
WO2003025000A2 (en) * | 2001-09-17 | 2003-03-27 | Nalan Utku | Peptides capable of modulating immune response |
US7175983B2 (en) | 2001-11-02 | 2007-02-13 | Abmaxis, Inc. | Adapter-directed display systems |
HUP0402155A2 (hu) * | 2001-11-16 | 2005-01-28 | Pharmexa A/S | Multimer fehérjék új immunogén mimetikumai széleskörű T-sejt-epitóp-inszertekkel |
GB2392158B (en) * | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
ES2559763T3 (es) * | 2002-09-10 | 2016-02-15 | Affimed Gmbh | Anticuerpo humano específico de CD3 con propiedades inmunosupresoras |
CA2532966C (en) * | 2003-07-15 | 2012-12-04 | Chugai Seiyaku Kabushiki Kaisha | Igm production by transformed cells and methods for quantifying said igm production |
CA2537900A1 (en) * | 2003-09-03 | 2005-04-28 | Dendritherapeutics, Inc. | Multiplex vaccines |
GB2408507B (en) * | 2003-10-06 | 2005-12-14 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof for specific targeting |
ATE518888T1 (de) | 2003-10-09 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | Stabilisierte lösung mit hoher igm-konzentration |
GB2409456B (en) * | 2003-10-30 | 2006-01-04 | Proimmune Ltd | Oligomeric receptor ligand pair member complexes |
EP1919949A2 (en) * | 2005-01-21 | 2008-05-14 | Nalan Utku | Hla fusion molecules and uses thereof |
US20140105980A1 (en) * | 2012-10-11 | 2014-04-17 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
EP3023436A1 (en) | 2007-07-03 | 2016-05-25 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
MX2014008146A (es) * | 2012-01-06 | 2016-02-03 | Univ Oregon Health & Science | Constructos de mhc parciales y metodos de uso. |
WO2013124474A2 (en) | 2012-02-23 | 2013-08-29 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10584381B2 (en) | 2012-08-14 | 2020-03-10 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10273541B2 (en) | 2012-08-14 | 2019-04-30 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9951386B2 (en) | 2014-06-26 | 2018-04-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
CN113528634A (zh) | 2012-08-14 | 2021-10-22 | 10X基因组学有限公司 | 微胶囊组合物及方法 |
EP3677310A1 (en) | 2012-10-08 | 2020-07-08 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
EP3567116A1 (en) | 2012-12-14 | 2019-11-13 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
KR102190198B1 (ko) | 2013-02-08 | 2020-12-14 | 10엑스 제노믹스, 인크. | 폴리뉴클레오티드 바코드 생성 |
EP3065771B1 (en) | 2013-11-04 | 2019-03-20 | UTI Limited Partnership | Methods and compositions for sustained immunotherapy |
WO2015157567A1 (en) | 2014-04-10 | 2015-10-15 | 10X Genomics, Inc. | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same |
RU2718692C2 (ru) | 2014-05-29 | 2020-04-13 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения |
EP3155426B1 (en) | 2014-06-13 | 2023-07-19 | Immudex ApS | General detection and isolation of specific cells by binding of labeled molecules |
EP3161160B1 (en) | 2014-06-26 | 2021-10-13 | 10X Genomics, Inc. | Methods of analyzing nucleic acids from individual cells or cell populations |
SG11201705615UA (en) | 2015-01-12 | 2017-08-30 | 10X Genomics Inc | Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same |
EP4286516A3 (en) | 2015-02-24 | 2024-03-06 | 10X Genomics, Inc. | Partition processing methods and systems |
US12011480B2 (en) | 2015-05-06 | 2024-06-18 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
GEP20217317B (en) | 2015-10-08 | 2021-11-10 | Macrogenics Inc | Combination therapy for the treatment of cancer |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
CN108431232B (zh) | 2015-12-04 | 2022-10-14 | 10X 基因组学有限公司 | 用于核酸分析的方法和组合物 |
US10011872B1 (en) | 2016-12-22 | 2018-07-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
CN117512066A (zh) | 2017-01-30 | 2024-02-06 | 10X基因组学有限公司 | 用于基于微滴的单细胞条形编码的方法和系统 |
CN111032850B (zh) | 2017-04-27 | 2024-08-13 | 朱诺治疗学有限公司 | 寡聚粒子试剂及其使用方法 |
CN109526228B (zh) | 2017-05-26 | 2022-11-25 | 10X基因组学有限公司 | 转座酶可接近性染色质的单细胞分析 |
US10400235B2 (en) | 2017-05-26 | 2019-09-03 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
EP3625361A1 (en) | 2017-11-15 | 2020-03-25 | 10X Genomics, Inc. | Functionalized gel beads |
US10829815B2 (en) | 2017-11-17 | 2020-11-10 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
CN112005115A (zh) | 2018-02-12 | 2020-11-27 | 10X基因组学有限公司 | 表征来自单个细胞或细胞群体的多种分析物的方法 |
WO2019195166A1 (en) | 2018-04-06 | 2019-10-10 | 10X Genomics, Inc. | Systems and methods for quality control in single cell processing |
WO2019217758A1 (en) | 2018-05-10 | 2019-11-14 | 10X Genomics, Inc. | Methods and systems for molecular library generation |
US20220275043A1 (en) * | 2018-07-17 | 2022-09-01 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
EP3898666A2 (en) | 2018-12-17 | 2021-10-27 | Immudex ApS | Panel comprising borrelia mhc multimers |
WO2022109339A1 (en) | 2020-11-20 | 2022-05-27 | Becton, Dickinson And Company | Use of dextramer in single cell analysis |
WO2022216974A1 (en) * | 2021-04-07 | 2022-10-13 | Repertoire Immune Medicines, Inc. | Peptide-mhc-immunoglobulin multimers and methods of use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015884A (en) * | 1996-03-28 | 2000-01-18 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6211342B1 (en) * | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
WO1998006749A2 (en) * | 1996-08-16 | 1998-02-19 | President And Fellows Of Harvard College | Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor |
AU5428598A (en) * | 1997-08-19 | 1999-03-08 | Mount Sinai School Of Medicine Of The City University Of New York, The | Epitope-bearing major histocompatibility complex class II element/immunoglobulin chimeric molecules |
-
1999
- 1999-02-19 JP JP2000532537A patent/JP2002504342A/ja not_active Withdrawn
- 1999-02-19 CA CA002321262A patent/CA2321262A1/en not_active Abandoned
- 1999-02-19 NZ NZ506071A patent/NZ506071A/en unknown
- 1999-02-19 IL IL13770699A patent/IL137706A0/xx unknown
- 1999-02-19 EP EP99908272A patent/EP1054984A1/en not_active Ceased
- 1999-02-19 BR BR9908082-6A patent/BR9908082A/pt not_active IP Right Cessation
- 1999-02-19 AU AU27748/99A patent/AU765378B2/en not_active Ceased
- 1999-02-19 WO PCT/US1999/003603 patent/WO1999042597A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2774899A (en) | 1999-09-06 |
AU765378B2 (en) | 2003-09-18 |
NZ506071A (en) | 2003-05-30 |
BR9908082A (pt) | 2000-10-31 |
EP1054984A1 (en) | 2000-11-29 |
WO1999042597A1 (en) | 1999-08-26 |
CA2321262A1 (en) | 1999-08-26 |
WO1999042597A9 (en) | 1999-11-04 |
JP2002504342A (ja) | 2002-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL137706A0 (en) | Mhc fusion proteins and conjugates | |
HUP0200414A2 (en) | Interferon-betha fusion proteins and uses | |
GB9718609D0 (en) | Fusion protein | |
ZA9811593B (en) | Substantially pure histidine-linked protein polymer conjugates | |
HUP0000302A3 (en) | Ob fusion protein compositions and methods | |
AU6058500A (en) | Fusion protein and uses thereof | |
GB9713980D0 (en) | New conjugates | |
TJ328B (en) | Interferron conjugates | |
EP1109921A4 (en) | FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE | |
AU4572899A (en) | Variant type ii tgf-beta receptor fusion proteins and methods | |
AU3562299A (en) | Inhibin-hbc fusion protein | |
IL142901A0 (en) | Opg fusion protein compositions and methods | |
EP1088888A4 (en) | MERGED PROTEIN | |
GB9705903D0 (en) | VP22 Proteins and uses thereof | |
GB9913437D0 (en) | Fusion proteins | |
AU9798398A (en) | Gfp-annexin fusion proteins | |
TW347944U (en) | Pivot joint structure | |
AU3923000A (en) | Agp-1 fusion protein compositions and methods | |
ZA984322B (en) | Sucrose-binding proteins | |
GB9816337D0 (en) | Proteins | |
GB9828704D0 (en) | Proteins | |
IL149202A0 (en) | Hedgehog fusion proteins and uses | |
AU2001261423A1 (en) | Vasodilator-thrombolytic fusion proteins and conjugates | |
EP1127066A4 (en) | MODIFIED PROTEINS | |
GB9803757D0 (en) | Fusion proteins |